Youhao Chen Selected Research

pamiparib

1/2024

Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Youhao Chen Research Topics

Disease

5	Neoplasms (Cancer) 01/2024 - 12/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2022 - 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2024
1	Neoplasm Metastasis (Metastasis) 06/2022
1	Chemical and Drug Induced Liver Injury 01/2022
1	Osteosarcoma (Osteogenic Sarcoma) 12/2021
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2018

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2022
2	Gefitinib (Iressa)FDA Link 09/2022 - 01/2022
2	CateninsIBA 01/2022 - 12/2021
1	pamiparibIBA 01/2024
1	niraparibIBA 01/2024
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2024
1	apatinibIBA 12/2023
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2023
1	Tumor Biomarkers (Tumor Markers)IBA 06/2022
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2018
1	TOR Serine-Threonine KinasesIBA 01/2018

Therapy/Procedure

1	Therapeutics 09/2022